查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
2023-2030 年全球人造子宫市场
市场调查报告书
商品编码
1217635

2023-2030 年全球人造子宫市场

Global Artificial Womb Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概览

人造子宫可以用来在体外培育胎儿。 因此，胎儿心臟和脐带是维持血液循环的条件。 如果满足这些条件，可以在分娩前从天然子宫转移到人工子宫模拟分娩。 EctoLife 是世界上第一个人造子宫设施，目前是一个完全由可再生能源提供动力的概念。 50 多年的全面和突破性的科学研究将使我们每年能够养育约 30,000 名婴儿。 这是居住在柏林的科学生物技术专家和传播者 Hashem Algaili 的心血结晶。 此外，胚胎可以在植入人造子宫之前进行基因操作。

市场动态

不孕□□症、流产、死产和人造子宫研究的兴起预计将在预测期内推动全球人造子宫市场的增长。

不孕□□症、流产和死产的增加将推动预测期内人造子宫市场的增长。

不孕□□症，或尝试超过一年后仍无法怀孕，对个人和夫妇来说都是困难的。 不孕症非常普遍，怀孕甚至会导致死产或流产。 全球不孕症患者数量的增加正在推动人造子宫市场的增长。 例如，UCLA Health 在 2020 年估计约有 15% 的夫妇难以怀孕。 此外，根据 Fertility Answers，大约 30% 的不孕症完全由女性引起，30% 完全由男性引起，30% 由双方混合引起，还有 10% 不明原因。是

此外，全球死产和流产的增加也促进了市场增长。 例如，根据 UNICEF.org 的数据，世界上每 16 秒就会发生一例死产，相当于每年约有 200 万婴儿死产，据说成本远远超过失去的生命。我来了。 到 2021 年，每 16 秒将有大约 190 万婴儿死产。 最新数据显示，2020年全球死产率为千分之13.9，其中40%以上发生在分娩过程中。 它对世界各地的妇女及其家庭产生了长期的创伤性影响，常常给社区带来深深的情绪困扰和污名化，即使在高收入国家也是如此。

此外，根据耶鲁大学医学院的数据，15-20% 的怀孕以流产告终，大约 2% 的女性连续流产两次，但这很可能是环境造成的。 根据 ACOG（美国妇产科学院）的数据，近 5% 的女性有 2 次或更多次流产，1% 有 3 次或更多次流产。 35 岁以上的女性和有过流产史的女性更有可能发生反復流产。 很少有流产病例被报导，因为许多妇女在知道自己怀孕之前就流产了，并且没有任何流产的迹像或症状。 大多数流产是由胚胎或胎儿的遗传异常引起的，例如额外的染色体或染色体突然出现。 这些是自然界中不存在且不太可能再次发生的突变。 但对于反復流产，情况就不同了，医生会寻找一种称为平衡易位的经典突变类型。 鑑于上述情况，预计在预测期内，不孕症、死产和流产的增加将提振全球人造子宫市场。

伦理问题和人造子宫的高成本可能会抑制全球人造子宫市场的增长。

但是，批准的道德要求作为市场限制了预测期内的增长。 同样，由于该技术具有创新性和安全性，因此建造人造子宫的成本高得令人望而却步，这使得中低收入者无法承受。 据推测，这些因素会阻碍未来几年的市场扩张。

COVID-19 的影响。

COVID-19 大流行期间 SARS-CoV-2 阳性母亲的流产、胎儿生长受限和死产等妊娠相关并发症的发生率似乎更高，这也是人类生育的未来。成为一个问题。 对此类未来大流行的担忧已将注意力集中在开发进行人类怀孕和分娩的新方法上。 因此，它对全球人造子宫市场的增长产生了积极影响。

内容

第一章研究方法与范围

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

第四章市场动态

  • 市场影响因素
    • 司机
      • 不孕症、流产和死产率增加
      • 调查与研发
    • 约束因素
      • 道德问题和高成本
    • 商机
    • 影响分析

第五章行业分析

  • 波特的五力分析
  • 定价分析
  • 未满足需求分析
  • 监管分析

第 6 章 COVID-19 分析

  • COVID-19 市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 总结

最终用户第 7 章

  • 研究中心
  • 专科医院
  • 其他

第8章按地区

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第9章竞争格局

  • 主要发展和战略
  • 公司股票分析
  • 产品基准

第十章公司简介

  • Juno Perinatal Healthcare
    • 公司简介
    • 产品组合和说明
    • 主要亮点
    • 财务摘要
  • EctoLife

第11章 DataM

简介目录
Product Code: DMMD6260

Market Overview

The global Artificial Womb market size was valued at US$ YY million in 2022 and is estimated to reach US$ YY million by 2030, growing at a CAGR of YY% during the forecast period (2023-2030).

An artificial womb can be used to carry a fetus to term outside of the body. As a result, requirements include a fetal heart and an umbilical cord to maintain circulation. When these conditions are satisfied, the baby can be transferred from a natural uterus to an artificial one, simulating giving birth before delivery. EctoLife, the first artificial womb facility in the world, is a concept that, for now, is entirely powered by renewable energy. It will have the capacity to grow around 30,000 babies every year, owing to the comprehensive and groundbreaking scientific investigation of over five decades. It is the brainchild of Hashem Al-Ghaili, a science biotechnologist and communicator from Berlin. It would also let them genetically engineer the embryo before implanting it into an artificial womb.

Market Dynamics

The rising number of infertility cases, miscarriages, and stillbirths and the research on artificial wombs will promote the global artificial womb market growth in the forecast period.

The growing number of infertility cases, miscarriages, and stillbirths drive the artificial womb market growth during the forecast period.

Infertility, or the inability to get pregnant even after attempting for over a year, can be challenging for individuals and couples. Infertility is fairly ordinary, and it can even mean getting pregnant but having stillbirths or miscarriages. The growing number of infertility cases globally boosts the artificial womb market growth. For instance, UCLA Health in 2020 estimated that about 15% of couples would have trouble conceiving. Also, according to Fertility Answers, about 30% of infertility cases can be attributed solely to the female, 30% can be attributed solely to the male, 30% can be attributed to a mixture of both partners, and 10% of cases have an unidentified reason.

Moreover, the growing incidences of stillbirths and miscarriages globally will also contribute to market growth. For example, according to UNICEF.org, a stillbirth occurs every 16 seconds worldwide, which means that every year, approximately 2 million babies are stillborn, a loss that goes far above the loss of life. Roughly 1.9 million babies, or one every 16 seconds, were stillborn in 2021. According to the latest data, the global stillbirth rate in 2020 was 13.9 stillbirths per 1,000 total births, and over 40% of all stillbirths happened during labor. It has a long-lasting traumatic influence on women and their families worldwide, who often bear deep psychological torment and stigma from their communities, even in high-income countries.

Similarly, according to Yale Medicine, almost 15 to 20% of pregnancies end in miscarriage, and roughly 2% of women experience two consecutive pregnancy losses, which could still be attributed to circumstance. Also, according to ACOG (American College of Obstetricians and Gynecologists), almost 5 % of women have two or more consecutive miscarriages, and 1 % might have three or above. The chance of recurrent miscarriage is elevated in women over 35 or with previous miscarriages. The cases of miscarriage are mostly underreported, as many women have miscarriages before they even know they are pregnant and do not experience any signs or symptoms of the miscarriage. The bulk of miscarriages happens due to genetic anomalies in the embryo or fetus, like an extra chromosome or skipping chromosomes. These are naturally unexpected mutations that are not probably to recur. In recurrent miscarriage, nevertheless, the situation is distinct, and the doctor will examine for a typical type of mutation called a balanced translocation. Thus, from the mentioned data, it is estimated that the growing cases of infertility, stillbirths and recurring miscarriages will push the global artificial womb market during the forecast period.

The ethical concerns and the high cost of the artificial womb will restrain the growth of the global artificial womb market.

However, the ethical requirements for approval function as a market will restrain its growth in the forecast period. Again, building an artificial womb will be highly expensive because the technology is innovative and safe, making it unaffordable to low and middle-income individuals. These factors are estimated to hamper the market expansion in the upcoming years.

COVID-19 Impact.

The COVID-19 pandemic created a concern about the future of human births since, during the pandemic period; it appeared to be a higher incidence of pregnancy-related complications in SARS-CoV-2 positive mothers, such as miscarriage, restricted fetal growth, or still-birth. Such future pandemic concerns are increasing the focus on developing new ways to carry out human gestation birth. Thus, positively impacting the global artificial womb market growth.

Segment Analysis

The research centers segment is expected to dominate the market throughout the forecast period (2022-2029).

Due to many initial projects in the pipeline, the research centers segment dominates the market. For instance, in 2020, the JUNO Perinatal Healthcare partnership is working to create a medical device, or "artificial womb," that enables extremely preterm infants to grow safely outside the womb. These infants will ultimately have better health chances than premature infants receiving standard care. The project received a Future and Emerging Technologies grant from the European program Horizon 2020 of almost 3 million euros. In this project, the researchers plan to finish a proof-of-principle in 5 years. And in 2021, using an artificial "womb" invented by scientists at the Weizmann Institute, early-stage mouse embryos with about 250 cells successfully developed into mouse fetuses with completely developed organs, which was made in Professor Jacob Hanna's Department of Molecular Genetics lab. The novel technique addresses a key issue in developmental biology: much of what is known about embryonic development comes from non-mammals like frogs or fish or is inferred from static photographs of mouse embryos because it is difficult to imagine or implant inside the uterus. With the help of this technique, Prof. Hanna and his team have generated fetuses that live until day 11, by which time the embryo has grown tenfold and is complete with blood, a beating heart, and a completely formed brain, which might lead to the development of fresh tactics for better medical care.

Geographical Analysis

Europe is expected to hold the largest global artificial womb market share.

The growing rate of infertility, stillbirths and miscarriage in Europe is expected to contribute to the region's hold on the global artificial womb market in the forecast period. For instance, according to NHS, in England, around 1 out of 250 births is a stillbirth. Not all the reasons for stillbirth are presently comprehended, and it's impossible to prevent every stillbirth. Also, according to the Tommy's Organization, a registered charity in England and Wales and Scotland, it is estimated that 1 in 4 pregnancies end in loss during pregnancy or birth, as there were around 500 miscarriages, 2,638 stillborn, and over 60,000 were born prematurely in the UK in 2020. Moreover, according to the National Bureau of Economic Research, as in many parts of the world, Europe has seen a rapid decline in fertility. For instance, according to Eurostat, over 4.071 million children were born in the EU, corresponding to a crude birth rate (the number of live births per 1 000 persons) of 9.1 in 2020. For comparison, the EU crude birth rate was 10.5 in 2000, 12.8 in 1985 and 16.4 in 1970.

Furthermore, the different initiatives in Europe to spread awareness about the declining birth rate, rising infertility rate and developments towards artificial womb research. For instance, the Wittgenstein Centre for Demography and Global Human Capital (IIASA, OeAW, University of Vienna) held its annual conference. The focus of the 2021 conference was on the causes and consequences of depopulation, an issue very much in the spotlight of the European Commission and beyond. Also, the Horizon 2020 EU program has awarded a research grant of €2.9 million to the Eindhoven University of Technology for researchers to develop artificial womb prototypes. In addition, Lisa Mandemaker presented a speculative design proposal for an artificial womb in close collaboration with Maxima Medical Centre (MMC) in the Netherlands. Thus, from the data mentioned, it is estimated that Europe will dominate the global artificial womb market throughout the forecast period.

Competitive Landscape

Currently, there is no present competition in the artificial womb market due to the absence of key players. Still, the market is expected to show moderate competition in the future owing to new players entering the market. Currently, only some players are working on the research project, which is expected to hold most of the market to themselves. For example,

Juno Perinatal Healthcare

Overview:

Juno Perinatal Healthcare is a spin-off enterprise of and confidante to the PLS project. The startup was established in July 2021 by engineers Jasmijn and Lyla Kok, medical engineer Beatrijs van der Hout, technician physician Dr. Myrthe van der Ven and Gynecologist prof. Dr. Guid Oei. Juno aspires to assure that the innovative perinatal life support technology developed in the PLS project will go to market.

Project:

The JUNO Perinatal Healthcare consortium is developing a medical device, an artificial womb, that supports the safe development of premature babies outside of the womb. Ultimately, these infants will have better health prospects than premature infants with conventional care.

The global artificial womb market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The Growing Number of Infertility Cases, Miscarriages, And Stillbirths
      • 4.1.1.2. Research and Developments
    • 4.1.2. Restraints
      • 4.1.2.1. The ethical concerns and the high cost
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Pricing Analysis
  • 5.3. Unmet Needs
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By End User

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 7.1.2. Market Attractiveness Index, By End User
  • 7.2. Research Centers
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Specialty Hospitals
  • 7.4. Others

8. By Region

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 8.1.2. Market Attractiveness Index, By Region
  • 8.2. North America
    • 8.2.1. Introduction
    • 8.2.2. Key Region-Specific Dynamics
    • 8.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 8.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 8.2.4.1. U.S.
      • 8.2.4.2. Canada
      • 8.2.4.3. Mexico
  • 8.3. Europe
    • 8.3.1. Introduction
    • 8.3.2. Key Region-Specific Dynamics
    • 8.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 8.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 8.3.4.1. Germany
      • 8.3.4.2. U.K.
      • 8.3.4.3. France
      • 8.3.4.4. Italy
      • 8.3.4.5. Spain
      • 8.3.4.6. Rest of Europe
  • 8.4. South America
    • 8.4.1. Introduction
    • 8.4.2. Key Region-Specific Dynamics
    • 8.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 8.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 8.4.4.1. Brazil
      • 8.4.4.2. Argentina
      • 8.4.4.3. Rest of South America
  • 8.5. Asia Pacific
    • 8.5.1. Introduction
    • 8.5.2. Key Region-Specific Dynamics
    • 8.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 8.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 8.5.4.1. China
      • 8.5.4.2. India
      • 8.5.4.3. Japan
      • 8.5.4.4. Australia
      • 8.5.4.5. Rest of Asia Pacific
  • 8.6. Middle East and Africa
    • 8.6.1. Introduction
    • 8.6.2. Key Region-Specific Dynamics
    • 8.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

9. Competitive Landscape

  • 9.1. Key Developments and Strategies
  • 9.2. Company Share Analysis
  • 9.3. Product Benchmarking

10. Company Profiles

  • 10.1. Juno Perinatal Healthcare
    • 10.1.1. Company Overview
    • 10.1.2. Product Portfolio and Description
    • 10.1.3. Key Highlights
    • 10.1.4. Financial Overview
  • 10.2. EctoLife

LIST NOT EXHAUSTIVE

11. DataM

  • 11.1. Appendix
  • 11.2. About Us and Services
  • 11.3. Contact Us